Arrowhead Reports Positive Phase 3 Data for Plozasiran in Hypertriglyceridemia Trial

Arrowhead Pharmaceuticals announced that its experimental drug plozasiran significantly reduced acute pancreatitis episodes in Phase 3 trials for patients with severe hypertriglyceridemia. The company now intends to submit a regulatory filing based on these clinical findings.

30 Aug, 16:07 — 30 Aug, 16:30

Post Share

Why this matters

Severe hypertriglyceridemia poses a high risk of life-threatening pancreatitis, yet effective long-term treatments remain limited. A successful approval would address an unmet clinical need and represent a major commercial milestone for Arrowhead's RNAi pipeline.

Key entitiesArrowhead Pharmaceuticals SHASTA-3 and SHASTA-4 Severe Hypertriglyceridemia

The Story

What 3 sources agree on, dispute, and miss

What sources agree on

Arrowhead Pharmaceuticals reported positive Phase 3 trial results for plozasiran
The drug significantly reduced acute pancreatitis events in patients with severe hypertriglyceridemia
The trials were designated as SHASTA-3 and SHASTA-4

Key claims3 agreed · 1 unverified

✓

Plozasiran targets severe hypertriglyceridemia (sHTG)

agreed·seeking-alphamorningstarinvesting-com

✓

Phase 3 program includes SHASTA-3 and SHASTA-4 trials

agreed·morningstarseeking-alpha

Arrowhead plans to submit a regulatory filing for plozasiran

unverified·investing-com

✓

Treatment reduces acute pancreatitis incidence in the target population

agreed·seeking-alphamorningstarinvesting-com

Where they diverge

Primary editorial focus

seeking-alpha

Emphasizes direct clinical outcomes and patient event reduction

investing-com

Prioritizes near-term regulatory filing strategy and commercial trajectory

Coverage gaps

Context on competing therapies and market share projections in the sHTG space

Reportedseeking-alpha

Missingmorningstarinvesting-com

The Story

Analyzing sources…

Source Diversity

Moderate (37/100)

3 sources25/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left

Center2

Center (2)

morningstarinvesting-com

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 1 region4/34

US3

ℹAll sources from US region

Political spectrum

LeftCenterRight

morningstar

investing-com

seeking-alpha

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

morningstarcentercenterneutral—Impartial financial analysis avoids ideological framing

investing-comcentercenterneutral—Standard business reporting maintains economic neutrality

seeking-alphacentercenter-rightanalyticalMixedPro-growth market orientation favors corporate interests

Coverage leans: center

Financial outlets maintain a neutral, data-driven approach focused on clinical milestones and regulatory timelines without overt political framing.

Sources

Showing 2 of 3 sources

morningstar7h ago

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Morningstar

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Morningstar

Read full article →

seeking-alphaMixed6h ago

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies

Read full article →

Coverage Timeline

First report: investing-com · 30 Aug, 15:36|Full coverage: 3 · 54m|Window: 54m

Left-leaningCenterRight-leaning

investing-com30 Aug, 15:36First to report

Arrowhead plans regulatory filing for plozasiran in sHTG

morningstar30 Aug, 16:07

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Morningstar

seeking-alpha30 Aug, 16:30Latest update

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies

Story evolution

Coverage evolved from a straightforward regulatory update to detailed clinical evaluation and eventual investment-focused analysis.

Initial AnnouncementAug 30, 15:36 UTC

Investing.com breaks the news focusing on upcoming regulatory filings

Data PresentationAug 30, 16:07 UTC

Morningstar covers the formal presentation of SHASTA-3/4 trial results

Investor AnalysisAug 30, 16:30 UTC

Seeking Alpha publishes deeper commentary on clinical outcomes and market impact

Arrowhead Reports Positive Phase 3 Data for Plozasiran in Hypertriglyceridemia Trial

Why this matters

The Story

What sources agree on

Key claims3 agreed · 1 unverified

Where they diverge

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Morningstar

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies

Coverage Timeline

Arrowhead plans regulatory filing for plozasiran in sHTG

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Morningstar

Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies

Story evolution

Related Stories

Pakistan to Honor Nurse Who Rescued Sole Newborn From Hospital Fire

Dutch Health Agency Warns of Lethal Trump-Shaped Ecstasy Pills

Austria Reports Record Heat-Related Deaths in June and July

Nigeria Urges Early Cancer Detection to Improve Treatment Outcomes

Political spectrum

Why this matters

Story evolution

The Story

What sources agree on

Key claims3 agreed · 1 unverified

Where they diverge

Coverage gaps

Coverage matrix